Icosavax to Participate in the Jefferies London Healthcare Conference
Icosavax to Participate in the Jefferies London Healthcare Conference
SEATTLE, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision of creating pan-respiratory vaccines for older adults, today announced that the company will participate in and host one-on-one meetings at the Jefferies London Healthcare Conference, taking place from November 14-16, 2023 in London, UK.
西雅圖，2023年11月8日（GLOBE NEWSWIRE）——生物製藥公司Icosavax, Inc.（納斯達克股票代碼：ICVX）今天宣佈，該公司將參與並主辦在傑富瑞倫敦醫療保健中心舉行的一對一會議，該公司最初的重點是危及生命的呼吸道疾病，並希望爲老年人研製泛呼吸道疫苗。會議將於 2023 年 11 月 14 日至 16 日在英國倫敦舉行。
Jefferies London Healthcare Conference
傑富瑞倫敦醫療保健會議
- Adam Simpson, Chief Executive Officer of Icosavax, will participate in a fireside chat in London on Wednesday, November 15 at 4:00 pm GMT (11:00 am ET).
- Icosavax首席執行官亞當·辛普森將於格林尼治標準時間11月15日星期三下午4點（美國東部時間上午11點）參加在倫敦舉行的爐邊談話。
Interested parties can register for and access the live webcast for this conference by visiting the "Events" section of the Icosavax website. The webcast replay will be available after the conclusion of the presentation.
感興趣的各方可以通過訪問” 註冊並訪問本次會議的網絡直播活動“Icosavax 網站上的欄目。網絡直播重播將在演講結束後播出。
About Icosavax
關於 Icosavax
Icosavax is a biopharmaceutical company leveraging its innovative VLP platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision for combination and pan-respiratory vaccines. Icosavax's VLP platform technology is designed to enable multivalent, particle-based display of complex viral antigens, which it believes will induce broad, robust, and durable protection against the specific viruses targeted. Icosavax's lead program is a combination vaccine candidate targeting respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), and its pipeline includes additional programs in influenza and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Icosavax was formed in 2017 to advance the breakthrough VLP technology from the Institute for Protein Design at the University of Washington with the goal to discover, develop, and commercialize vaccines against infectious diseases. Icosavax is located in Seattle.
Icosavax是一家生物製藥公司，利用其創新的VLP平台技術開發傳染病疫苗，最初的重點是危及生命的呼吸道疾病，願景是聯合疫苗和泛呼吸道疫苗。Icosavax 的 VLP 平台技術旨在實現基於顆粒的多價顯示覆雜的病毒抗原，它認爲這將對目標特定病毒提供廣泛、可靠和持久的保護。Icosavax的牽頭項目是針對呼吸道合胞病毒（RSV）和人類偏肺病毒（hmPV）的聯合候選疫苗，其在研項目包括流感和嚴重急性呼吸綜合徵冠狀病毒2（SARS-CoV-2）的其他項目。Icosavax 成立於 2017 年，旨在推進華盛頓大學蛋白質設計研究所的突破性 VLP 技術，目標是發現、開發和商業化針對傳染病的疫苗。Icosavax 位於西雅圖。
For more information, visit .
欲了解更多信息，請訪問 。
Media Contact:
Jessica Yingling, Ph.D.,
Little Dog Communications Inc.
jessica@litldog.com
858.344.8091
媒體聯繫人：
傑西卡·英靈博士，
小狗通訊公司
jessica@litldog.com
858.344.8091
Investor Contact:
Laurence Watts
Gilmartin Group, LLC
laurence@gilmartinir.com
619.916.7620
投資者聯繫人：
勞倫斯·沃茨
吉爾馬丁集團有限責任公司
laurence@gilmartinir.com
619.916.7620